MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjaf210

Медицинская библиотека · Journal of Crohn's & colitis · 2025

Systematic review and network meta-analysis: evaluating the impact of advanced therapies for moderate-to-severe ulcerative colitis on health-related quality of life.

Katsoula Anastasia, Paschos Paschalis, Malandris Konstantinos, Kalogirou Maria-Styliani, Haidich Anna-Bettina, Giouleme Olga, Tsapas Apostolos

СтатьяNetwork Meta-AnalysisСистематический обзорПеревод в очереди

Аннотация

INTRODUCTION

Ulcerative colitis (UC) is a chronic inflammatory disease that impairs health-related quality of life (HRQoL). We evaluated the effect of approved therapies on HRQoL in adults with moderate-to-severe UC.

METHODS

We systematically searched Medline, Embase, CENTRAL, and gray literature through December 2024 for randomized controlled trials (RCTs) of approved therapies. The primary outcome was change in Inflammatory Bowel Disease Questionnaire (IBDQ) score during induction and maintenance. Secondary outcomes included changes in Short Form-36 (SF-36) Mental and Physical Component Scores, Work Productivity and Activity Impairment in UC (WPAI-UC), and rates of IBDQ response (≥16-point increase) and remission (score ≥170). Minimal clinically important differences were prespecified. Subgroup analyses based on prior biologic exposure were performed for primary outcome. Frequentist random-effects network meta-analyses were conducted, and confidence in estimates was assessed using the CINeMA (Confidence In Network Meta-Analysis) framework.

RESULTS

Twenty-eight RCTs were included; 26 reported HRQoL outcomes during induction and 15 during maintenance. During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30 mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated. SF-36 improvements were modest overall, with upadacitinib and vedolizumab showing selective advantages, while WPAI-UC benefits were observed with upadacitinib, vedolizumab, and ustekinumab. Upadacitinib consistently ranked highest in IBDQ response and remission, while other therapies showed variable efficacy across outcomes.

DISCUSSION: Advanced therapies vary in their impact on HRQoL, with some demonstrating clinically meaningful improvements in UC. These findings support integrating HRQoL into treatment selection and shared decision-making.

Для цитирования: Katsoula Anastasia, Paschos Paschalis, Malandris Konstantinos, Kalogirou Maria-Styliani, Haidich Anna-Bettina, Giouleme Olga, Tsapas Apostolos. Systematic review and network meta-analysis: evaluating the impact of advanced therapies for moderate-to-severe ulcerative colitis on health-related quality of life.. Journal of Crohn's & colitis. 2025. DOI: 10.1093/ecco-jcc/jjaf210.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.